199 related articles for article (PubMed ID: 23607294)
1. Decorin is down-regulated in multiple myeloma and MGUS bone marrow plasma and inhibits HGF-induced myeloma plasma cell viability and migration.
Kristensen IB; Pedersen L; Rø TB; Christensen JH; Lyng MB; Rasmussen LM; Ditzel HJ; Børset M; Abildgaard N
Eur J Haematol; 2013 Sep; 91(3):196-200. PubMed ID: 23607294
[TBL] [Abstract][Full Text] [Related]
2. Hepatocyte growth factor pathway upregulation in the bone marrow microenvironment in multiple myeloma is associated with lytic bone disease.
Kristensen IB; Christensen JH; Lyng MB; Møller MB; Pedersen L; Rasmussen LM; Ditzel HJ; Abildgaard N
Br J Haematol; 2013 May; 161(3):373-82. PubMed ID: 23431957
[TBL] [Abstract][Full Text] [Related]
3. A HGF/cMET autocrine loop is operative in multiple myeloma bone marrow endothelial cells and may represent a novel therapeutic target.
Ferrucci A; Moschetta M; Frassanito MA; Berardi S; Catacchio I; Ria R; Racanelli V; Caivano A; Solimando AG; Vergara D; Maffia M; Latorre D; Rizzello A; Zito A; Ditonno P; Maiorano E; Ribatti D; Vacca A
Clin Cancer Res; 2014 Nov; 20(22):5796-807. PubMed ID: 25212607
[TBL] [Abstract][Full Text] [Related]
4. Pentraxin 3 (PTX3) inhibits plasma cell/stromal cell cross-talk in the bone marrow of multiple myeloma patients.
Basile A; Moschetta M; Ditonno P; Ria R; Marech I; De Luisi A; Berardi S; Frassanito MA; Angelucci E; Derudas D; Specchia G; Curci P; Pavone V; Rossini B; Ribatti D; Bottazzi B; Mantovani A; Presta M; Dammacco F; Vacca A
J Pathol; 2013 Jan; 229(1):87-98. PubMed ID: 22847671
[TBL] [Abstract][Full Text] [Related]
5. Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma.
Paiva B; Pérez-Andrés M; Vídriales MB; Almeida J; de las Heras N; Mateos MV; López-Corral L; Gutiérrez NC; Blanco J; Oriol A; Hernández MT; de Arriba F; de Coca AG; Terol MJ; de la Rubia J; González Y; Martín A; Sureda A; Schmidt-Hieber M; Schmitz A; Johnsen HE; Lahuerta JJ; Bladé J; San-Miguel JF; Orfao A; ;
Leukemia; 2011 Apr; 25(4):697-706. PubMed ID: 21252988
[TBL] [Abstract][Full Text] [Related]
6. Bone marrow fibroblasts overexpress miR-27b and miR-214 in step with multiple myeloma progression, dependent on tumour cell-derived exosomes.
Frassanito MA; Desantis V; Di Marzo L; Craparotta I; Beltrame L; Marchini S; Annese T; Visino F; Arciuli M; Saltarella I; Lamanuzzi A; Solimando AG; Nico B; De Angelis M; Racanelli V; Mariggiò MA; Chiacchio R; Pizzuti M; Gallone A; Fumarulo R; D'Incalci M; Vacca A
J Pathol; 2019 Feb; 247(2):241-253. PubMed ID: 30357841
[TBL] [Abstract][Full Text] [Related]
7. Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
Kyle RA; San-Miguel JF; Mateos MV; Rajkumar SV
Hematol Oncol Clin North Am; 2014 Oct; 28(5):775-90. PubMed ID: 25212882
[TBL] [Abstract][Full Text] [Related]
8. Higher Decorin Levels in Bone Marrow Plasma Are Associated with Superior Treatment Response to Novel Agent-Based Induction in Patients with Newly Diagnosed Myeloma - A Retrospective Study.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Hou HA; Chou WC; Chou SC; Hsu SC; Ko BS; Lu HY; Tsay W; Tien HF
PLoS One; 2015; 10(9):e0137552. PubMed ID: 26379028
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemical analysis of hepatocyte growth factor and c-Met in plasma cell disease.
Wader KF; Fagerli UM; Børset M; Lydersen S; Hov H; Sundan A; Bofin A; Waage A
Histopathology; 2012 Feb; 60(3):443-51. PubMed ID: 22276607
[TBL] [Abstract][Full Text] [Related]
10. Metabolomic and Lipidomic Profiling of Bone Marrow Plasma Differentiates Patients with Monoclonal Gammopathy of Undetermined Significance from Multiple Myeloma.
Gonsalves WI; Broniowska K; Jessen E; Petterson XM; Bush AG; Gransee J; Lacy MQ; Hitosugi T; Kumar SK
Sci Rep; 2020 Jun; 10(1):10250. PubMed ID: 32581232
[TBL] [Abstract][Full Text] [Related]
11. Bone marrow plasma level of decorin may be associated with improved treatment outcomes in a subset of multiple myeloma patients.
Huang SY; Lin HH; Yao M; Tang JL; Wu SJ; Chou WC; Hsu SC; Ko BS; Tien HF
J Formos Med Assoc; 2022 Mar; 121(3):643-651. PubMed ID: 34246509
[TBL] [Abstract][Full Text] [Related]
12. MYC protein expression is detected in plasma cell myeloma but not in monoclonal gammopathy of undetermined significance (MGUS).
Xiao R; Cerny J; Devitt K; Dresser K; Nath R; Ramanathan M; Rodig SJ; Chen BJ; Woda BA; Yu H
Am J Surg Pathol; 2014 Jun; 38(6):776-83. PubMed ID: 24705315
[TBL] [Abstract][Full Text] [Related]
13. A selective c-met inhibitor blocks an autocrine hepatocyte growth factor growth loop in ANBL-6 cells and prevents migration and adhesion of myeloma cells.
Hov H; Holt RU; Rø TB; Fagerli UM; Hjorth-Hansen H; Baykov V; Christensen JG; Waage A; Sundan A; Børset M
Clin Cancer Res; 2004 Oct; 10(19):6686-94. PubMed ID: 15475459
[TBL] [Abstract][Full Text] [Related]
14. CD229 Expression on Bone Marrow Plasma Cells from Patients with Multiple Myeloma and Monoclonal Gammopathies of Uncertain Significance.
Carulli G; Buda G; Azzarà A; Ciancia EM; Sammuri P; Domenichini C; Guerri V; Petrini M
Acta Haematol; 2016; 135(1):11-4. PubMed ID: 26303094
[No Abstract] [Full Text] [Related]
15. Upregulation of Syndecan-1 in the bone marrow microenvironment in multiple myeloma is associated with angiogenesis.
Andersen NF; Kristensen IB; Preiss BS; Christensen JH; Abildgaard N
Eur J Haematol; 2015 Sep; 95(3):211-7. PubMed ID: 25353275
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-6 is expressed by plasma cells from patients with multiple myeloma and monoclonal gammopathy of undetermined significance.
Sati HI; Apperley JF; Greaves M; Lawry J; Gooding R; Russell RG; Croucher PI
Br J Haematol; 1998 May; 101(2):287-95. PubMed ID: 9609524
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.
Skrtić A; Korać P; Krišto DR; Ajduković Stojisavljević R; Ivanković D; Dominis M
Hum Pathol; 2010 Dec; 41(12):1702-10. PubMed ID: 20800871
[TBL] [Abstract][Full Text] [Related]
18. Anti-c-MET Nanobody - a new potential drug in multiple myeloma treatment.
Slørdahl TS; Denayer T; Moen SH; Standal T; Børset M; Ververken C; Rø TB
Eur J Haematol; 2013 Nov; 91(5):399-410. PubMed ID: 23952536
[TBL] [Abstract][Full Text] [Related]
19. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
20. The hepatocyte growth factor/Met pathway controls proliferation and apoptosis in multiple myeloma.
Derksen PW; de Gorter DJ; Meijer HP; Bende RJ; van Dijk M; Lokhorst HM; Bloem AC; Spaargaren M; Pals ST
Leukemia; 2003 Apr; 17(4):764-74. PubMed ID: 12682635
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
